Moderna’s Concerns About Omicron Outlook Spark Market Slump
- One founder says the mutations point to ‘serious threat’
- CEO Stephane Bancel spooks markets with comments to FT
This article is for subscribers only.
Moderna Inc.’s top executives reiterated that the omicron variant’s many mutations suggest new vaccines will be needed, triggering a drop in financial markets.
“The number of mutations on this virus are surprising,” co-founder Noubar Afeyan said in a Bloomberg Television interview. “We have to take it for the serious threat that it poses.”